On Jan. 29, 2021, Rigel Pharma announced it has been awarded $16.5 million by the U.S. Department of Defense’s (DOD) to support Rigel’s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients.

Fostamatinib is marketed in the U.S. as TAVALISSEﾮ (fostamatinib disodium hexahydrate) tablets, and was approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP).